- Home
- DAWN vs SIBN Comparison
DAWN vs SIBN Comparison
Compare DAWN & SIBN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DAWN
- SIBN
- Stock Information
- Founded
- DAWN 2018
- SIBN 2008
- Country
- DAWN United States
- SIBN United States
- Employees
- DAWN N/A
- SIBN N/A
- Industry
- DAWN Biotechnology: Pharmaceutical Preparations
- SIBN Medical/Dental Instruments
- Sector
- DAWN Health Care
- SIBN Health Care
- Exchange
- DAWN Nasdaq
- SIBN Nasdaq
- Market Cap
- DAWN 624.8M
- SIBN 717.0M
- IPO Year
- DAWN 2021
- SIBN 2018
- Fundamental
- Price
- DAWN $7.19
- SIBN $15.60
- Analyst Decision
- DAWN Strong Buy
- SIBN Strong Buy
- Analyst Count
- DAWN 7
- SIBN 4
- Target Price
- DAWN $27.86
- SIBN $25.75
- AVG Volume (30 Days)
- DAWN 1.1M
- SIBN 308.9K
- Earning Date
- DAWN 10-29-2025
- SIBN 11-11-2025
- Dividend Yield
- DAWN N/A
- SIBN N/A
- EPS Growth
- DAWN N/A
- SIBN N/A
- EPS
- DAWN N/A
- SIBN N/A
- Revenue
- DAWN $187,638,000.00
- SIBN $185,262,000.00
- Revenue This Year
- DAWN $12.56
- SIBN $19.92
- Revenue Next Year
- DAWN $48.02
- SIBN $16.28
- P/E Ratio
- DAWN N/A
- SIBN N/A
- Revenue Growth
- DAWN 2190.50
- SIBN 22.93
- 52 Week Low
- DAWN $5.64
- SIBN $11.70
- 52 Week High
- DAWN $16.76
- SIBN $20.05
- Technical
- Relative Strength Index (RSI)
- DAWN 52.01
- SIBN 42.73
- Support Level
- DAWN $7.18
- SIBN $15.95
- Resistance Level
- DAWN $7.58
- SIBN $16.36
- Average True Range (ATR)
- DAWN 0.27
- SIBN 0.48
- MACD
- DAWN -0.03
- SIBN -0.00
- Stochastic Oscillator
- DAWN 33.92
- SIBN 11.31
About DAWN Day One Biopharmaceuticals Inc.
Day One Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is dedicated towards developing and commercializing targeted therapies for patients of all ages with genetically defined cancers. Initially, it focuses on clinical development efforts on pediatric patients living with cancer, a vulnerable population that has been underserved in the recent revolution in targeted therapeutics and immuno-oncology. The product candidate, DAY101, is an oral, brain-penetrant, highly-selective type II pan-rapidly accelerated fibrosarcoma, or pan-RAF, and kinase inhibitor.
About SIBN SI-BONE Inc.
SI-BONE Inc is a medical device company, that develops and commercializes a proprietary minimally invasive surgical implant system in the United States and Internationally. Its products include a series of patented titanium implants and the instruments used to implant them, as well as implantable bone products such as iFuse-3D, iFuse-TORQ and iFuse Bedrock Granite which have applications across sacroiliac joint dysfunction and fusion, adult spinal deformity and degeneration, and pelvic trauma.